Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Imunon, Inc.IMNN · Entity 8041 | CFO | January 02, 2026 | January 06, 2026 |
| Timber Pharmaceuticals, Inc.TMBR · Entity 110330 | Controller | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Imunon, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 · Expires 2036-01-02 | Direct | 9,050 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 9,050 · Balance 9,050 F1: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant
F2: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.
Timber Pharmaceuticals, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2030-06-07 | Direct | 38,833 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 38,833 · Balance 38,833 F1: 25% of the options vest on June 8, 2021, and the remaining shares will become exercisable in equal 36 monthly installments beginning on July 8, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options vest on June 8, 2021, and the remaining shares will become exercisable in equal 36 monthly installments beginning on July 8, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:11 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 9,050 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-26-000615 · rdgdoc.xml · derivative · entry 1 Bragg Kimberly · CIK 0001814159 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,050 Underlying: Common Stock · 9,050 shares Expires 2036-01-02 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:27 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 667 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001437749-25-025090 · rdgdoc.xml · derivative · entry 1 Bragg Kimberly · CIK 0001814159 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 667 shares Expires 2035-08-04 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 18:55 UTC | Timber Pharmaceuticals, Inc. TMBR · Entity 110330 | GrantStock Option (right to buy) · Derivative | 38,833 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0000905718-20-000552 · timber_fm4jun82020.xml · derivative · entry 1 Bragg Kimberly · CIK 0001814159 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,833 Underlying: Common Stock, par value $0.001 per share · 38,833 shares Expires 2030-06-07 F1 · derivative.exercise_date: 25% of the options vest on June 8, 2021, and the remaining shares will become exercisable in equal 36 monthly installments beginning on July 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.